Study shows oral vaccine for UTI is potential alternative to antibiotics

Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs are presented this weekend at the European Association of Urology (EAU) Congress in Paris.

They show that in both men and women with recurrent UTIs, 54 per cent of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published by the end of 2024.

UTIs are the most common bacterial infection.

They are experienced by half of all women and one in five men and can be painful and uncomfortable.

Recurrent infections, needing short-term antibiotic treatment, develop in between 20 to 30 per cent of cases.

With antibiotic-resistant UTIs now on the rise and drugs becoming less effective, new ways of preventing and treating these infections are needed.

Carried out by clinicians at the UK’s Royal Berkshire Hospital, this long-term follow-up looked at the safety and efficacy of the MV140 vaccine in 89 patients originally treated privately at The Urology Partnership Reading.

MV140 is a new vaccine for recurrent UTIs and is administered with two sprays of a pineapple-flavoured suspension under the tongue every day for three months.

While researchers have previously studied MV140’s short-term safety and effectiveness, this is the first long-term follow-up study to report globally.

Dr Bob Yang,Consultant Urologist at the Royal Berkshire NHS Foundation Trust, who co-led the research, said “Before having the vaccine, all our participants suffered with recurrent

UTIs, and for many women, these can be difficult to treat.

Nine years after first receiving this new UTI vaccine, around half of participants remained infection free. Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe. Many of those who did get a UTI told us that simply drinking plenty of water was enough to treat it.”

“This is a veryeasyvaccinetoadministerandcouldbegivenbyGPsasa3-month course. Many of our participants told us that having the vaccine restored their quality of life. While we’re yet to look at the effect of this vaccine in different patient groups, this follow-up data suggests it could be a game changer for UTI prevention if it’s offered widely, reducing the need for antibiotic treatments.”

In their original trial, patients were initially followed-up for 12 months and data from the women in the cohort was published in BJU International 2017.

For their nine-year follow- up study, the researchers analysed data from the electronic health records of their original cohort.

They interviewed participants about their experience of UTIs since receiving the vaccine and asked them about side effects.

Forty-eightparticipantsremainedentirelyinfectionfreeduringthenine-yearfollow-up.The average infection-free period across the cohort was 54.7 months (four and a half years) –

56.7months for women and 44.3 months, one year less, for men.

40% of participants reported having repeat doses of the vaccine after one or two years.